Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
[5] FDAs concerns fell into four connected areas: Characterization and identity: FDA cited inconsistent naming and inadequate information about critical quality attributes needed to establish identity, purity, and quality for the proposed compounded products
Therapeutics for nonneoplastic diseases The exploration of therapeutics targeting p53 in nontumorous diseases is not as widespread as that in cancers
This is where reduced glutathione comes in
The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis
any outlier triggers a root-cause huddle moderated by the SPAQI champion [6,9]
Nature 409(6822):860921
US$ 28.82
US$ 21.89
US$ 24.14
US$ 26.84
US$ 28.00
US$ 24.50
US$ 27.13
US$ 27.67
